Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis.

@article{liu2026impact,
  title = {{Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis.}},
  author = {Jinxia Liu and Fernando Garcia-Guevara and Jane Macnaughtan and Yi Jin and Ainhoa Ferret-Miñana and Frederick Clasen and Nicholas Yuen and Ramón Garcia Maset and Javier Ramón-Azcón and Annarein J C Kerbert and Theo Portlock and Javier Martinez and Abeba Habtesion and Alexandra Phillips and Francesco De Chiara and Ganesh Ingavle and Tom Baldwin and Cesar Jimenez and Giacomo Zaccherini and Katherine Husi and Miguel Rodriguez-Gandia and Paul Cordero-Sanchez and Junpei Soeda and Jude A Oben and Karen Church and Jia V Li and Aarti Jalan and Adria Juanola and Elsa Sola and Simon Eaton and Carrie Morgan and Thomas Avery and Michal Kowalski and Daniel Green and Amir Gander and Lindsey Ann Edwards and I Jane Cox and Helena Cortez-Pinto and Reiner Wiest and Francois Durand and Paolo Caraceni and Roberto Elosua and Joan Vila and Marco Pavesi and Vicente Arroyo and Nathan Davies and Rajeshwar P Mookerjee and Susan Sandeman and Gautam Mehta and Julian R Marchesi and Agustin Albillos and Jennifer L Rohn and Fausto Andreola and Saeed Shoaie and Rajiv Jalan},
  journal = {Liver international : official journal of the International Association for the Study of the Liver},
  year = {2026},
  month = oct,
  doi = {10.1111/liv.70933},
  url = {https://europepmc.org/article/MED/42905905},
  note = {CC BY},
}

TY  - JOUR
TI  - Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis.
AU  - Jinxia Liu
AU  - Fernando Garcia-Guevara
AU  - Jane Macnaughtan
AU  - Yi Jin
AU  - Ainhoa Ferret-Miñana
AU  - Frederick Clasen
AU  - Nicholas Yuen
AU  - Ramón Garcia Maset
AU  - Javier Ramón-Azcón
AU  - Annarein J C Kerbert
AU  - Theo Portlock
AU  - Javier Martinez
AU  - Abeba Habtesion
AU  - Alexandra Phillips
AU  - Francesco De Chiara
AU  - Ganesh Ingavle
AU  - Tom Baldwin
AU  - Cesar Jimenez
AU  - Giacomo Zaccherini
AU  - Katherine Husi
AU  - Miguel Rodriguez-Gandia
AU  - Paul Cordero-Sanchez
AU  - Junpei Soeda
AU  - Jude A Oben
AU  - Karen Church
AU  - Jia V Li
AU  - Aarti Jalan
AU  - Adria Juanola
AU  - Elsa Sola
AU  - Simon Eaton
AU  - Carrie Morgan
AU  - Thomas Avery
AU  - Michal Kowalski
AU  - Daniel Green
AU  - Amir Gander
AU  - Lindsey Ann Edwards
AU  - I Jane Cox
AU  - Helena Cortez-Pinto
AU  - Reiner Wiest
AU  - Francois Durand
AU  - Paolo Caraceni
AU  - Roberto Elosua
AU  - Joan Vila
AU  - Marco Pavesi
AU  - Vicente Arroyo
AU  - Nathan Davies
AU  - Rajeshwar P Mookerjee
AU  - Susan Sandeman
AU  - Gautam Mehta
AU  - Julian R Marchesi
AU  - Agustin Albillos
AU  - Jennifer L Rohn
AU  - Fausto Andreola
AU  - Saeed Shoaie
AU  - Rajiv Jalan
PY  - 2026
DA  - 2026/10/30
JO  - Liver international : official journal of the International Association for the Study of the Liver
DO  - 10.1111/liv.70933
UR  - https://europepmc.org/article/MED/42905905
AB  - Background & aims  YAQ001 is a novel, non-absorbable, gut-restricted, multiporous, carbon bead adsorbent. Pre-clinical studies and a clinical trial suggested its therapeutic potential and safety in patients with cirrhosis. This substudy aimed to explore the effects of YAQ001 on the gut microbiome and their exploratory association with biomarkers of gut permeability and systemic inflammation.Methods  Twenty-eight-patients with cirrhosis were randomized (double-blind) to receive YAQ001 (4 g once daily) or placebo. Gut microbiome and biomarkers of inflammation and gut permeability were assessed at baseline, after 4 and 12 weeks. Changes in biomarkers and relationship with microbiome composition and gene profiling were assessed. The effect of YAQ001 on Klebsiella pneumoniae biofilms was assessed in vitro.Results  Overall alpha and beta diversity remained unaltered. YAQ001 increased the abundance of bacteria associated with improved gut health such as Adlercreutzia equolifaciens, a bacterium commonly depleted in liver disease, and decreased the abundance of bacteria associated with infections and poor outcomes such as Klebsiella pneumonia, and Streptococcus mutans. YAQ001 impacted positively on virulence factors such as siderophores, fimbriae structures, and lipopolysaccharides that are associated with inflammation and invasion. Antibiotic resistance genes decreased significantly in the YAQ001 group. These changes were associated with a reduction in markers of gut permeability and systemic inflammation. YAQ001 prevented K. pneumoniae biofilms in vitro.Conclusion  YAQ001 was associated with favourable compositional shifts and trends towards reduced virulence-related gene signatures in the gut microbiome, alongside trends towards improved inflammatory biomarkers. The in vitro anti-biofilm effect of YAQ001 warrants further mechanistic investigation. The findings position YAQ001 as a potential microbiome therapeutic.
SN  - 1478-3223
SN  - 1478-3231
ER  -